证券代码：000597 证券简称：东北制药 公告编号：2023-046 东北制药集团股份有限公司 关于召开公司 2023 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东大会届次：本次股东大会为公司 2023 年第二次临时股东大会。 2.股东大会的召集人：公司董事会。2023 年 8 月 22 日，东北制药集团股份 有限公司（以下简称"公司"）第九届董事会第十八次会议，以同意 10 票，反对 0 票，弃权 0 票,审议通过了《关于召开公司 2023 年第二次临时股东大会的议案》。 3.会议召开的合法、合规性：公司第九届董事会第十八次会议决定召开本次 股东大会。本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性 文件、深圳证券交易所业务规则和《东北制药集团股份有限公司章程》等规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2023 年 9 月 7 日下午 14：00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2023 年 9 月 7 日上午 9：15 至 ...

东北制药集团股份有限公司（以下简称"公司"）于 2023 年 7 月 25 日召开 第九届董事会第十七次会议、第九届监事会第十三次会议；2023 年 8 月 10 日召 开 2023 年第一次临时股东大会，审议通过了《关于拟回购注销 2022 年限制性股 票激励计划部分已获授但尚未解除限售的限制性股票的议案》。公司拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除限售的限制性股票 521.3 万股。 具体内容详见 2023 年 7 月 26 日刊登于《证券时报》《中国证券报》《上海证券 报》以及巨潮资讯网上的《东北制药集团股份有限公司关于拟回购注销 2022 年限 制性股票激励计划部分已获授但尚未解除限售的限制性股票的公告》（公告编号： 2023-035）。 本次回购注销完成后，公司总股本将减少 5,213,000 股，注册资本将相应减 少 5,213,000 元（最终结果以中国证券登记结算有限责任公司深圳分公司确认为 准），现根据《中华人民共和国公司法》等相关法律、法规的规定，公司特此向 债权人发出通知。 公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华人民共 和国公司法》等相关法律 ...

北京德恒律师事务所 关于东北制药集团股份有限公司 2023 年第一次临时股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于东北制药集团股份有限公司 2023 年第一次临时股东大会的法律意见 北京德恒律师事务所 关于东北制药集团股份有限公司 2023 年第一次临时股东大会的 法律意见 德恒 01G20200554-06 号 致：东北制药集团股份有限公司 （六）本次会议其他会议文件。 东北制药集团股份有限公司（以下简称"公司"）2023 年第一次临时股东 大会（以下简称"本次会议"）于 2023 年 8 月 10 日（星期四）召开。北京德恒 律师事务所接受东北制药集团股份有限公司（以下简称"公司"）委托，指派李 哲律师、王冰律师（以下简称"德恒律师"）出席本次会议。根据《中华人民共 和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）、 《东北制药集团股份有限公司章程》（以下简称"《 ...

证券代码：000597 证券简称：东北制药 公告编号：2023-040 一、会议召开和出席情况 （一）会议召开情况 特别提示： 1．本次股东大会未出现否决议案的情形； 2．本次股东大会不涉及变更以往股东大会已通过的决议； 3．本次股东大会审议事项全部获得通过。 东北制药集团股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 1.本次会议召开的时间： （1）现场会议召开时间：2023 年 8 月 10 日下午 14：00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2023 年 8 月 10 日上午 9：15 至 9：25，9：30 至 11：30，下午 13：00 至 15：00； 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2023 年 8 月 10 日上午 9：15 至下午 15：00。 2.现场会议地点：沈阳经济技术开发区昆明湖街 8 号，东北制药集团股份有 限公司。 3.召开方式：采用现场表决与网络投票相结合的方式召开。 4.召集人：公司董事会 5.主持人：公司董事 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 2,354,060,515.14, a slight increase of 0.02% compared to CNY 2,353,478,963.48 in the same period last year[5] - Net profit attributable to shareholders was CNY 70,050,130.06, representing a year-on-year increase of 2.51% from CNY 68,332,634.61[5] - Net profit for Q1 2023 was CNY 73,273,910.10, compared to CNY 72,594,482.98 in Q1 2022, showing an increase of 0.94%[16] - The total comprehensive income attributable to the parent company was CNY 69,857,492.43, compared to CNY 68,201,513.99 in the previous period, reflecting an increase of approximately 2.43%[17] - The total comprehensive income for minority shareholders was CNY 3,231,921.10, down from CNY 4,263,275.46 in the previous period, reflecting a decrease of approximately 24.23%[17] Cash Flow - The net cash flow from operating activities was CNY 114,351,104.00, down 56.42% from CNY 262,374,644.73 in the same period last year[5] - The net cash flow from operating activities was CNY 114,351,104.00, a decrease of 56.36% from CNY 262,374,644.73 in the previous period[20] - The company reported a significant increase of 454% in net cash flow from financing activities, amounting to CNY 327,000,000.00 due to increased bank loans[8] - The net cash flow from financing activities was CNY 327,001,976.11, compared to a negative cash flow of CNY -128,893,906.16 in the previous period, indicating a significant turnaround[20] - The total cash inflow from financing activities was CNY 2,600,055,207.14, compared to CNY 1,949,819,609.56 in the previous period, marking an increase of approximately 33.43%[20] - The cash outflow from operating activities totaled CNY 2,136,220,717.35, an increase of 18.56% from CNY 1,802,114,156.30 in the previous period[20] - The company recorded a net cash outflow from investing activities of CNY -28,879,694.93, an improvement from CNY -74,960,730.69 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 14,186,126,115.14, an increase of 2.72% from CNY 13,810,327,971.57 at the end of the previous year[5] - The total assets of the company reached CNY 14,186,126,115.14, up from CNY 13,810,327,971.57, indicating an increase of 2.72%[14] - The total liabilities increased to CNY 9,357,664,935.95 from CNY 9,097,072,806.91, which is an increase of 2.86%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 81,145, with the top two shareholders holding a combined 53.84% of the shares[9] Expenses - The net profit after deducting non-recurring gains and losses decreased by 16.00% to CNY 44,510,180.83 from CNY 52,985,985.93 in the previous year[5] - Research and development expenses for the period were CNY 12,680,000.00, a decrease of 40% compared to the previous year[7] - R&D expenses decreased to CNY 12,681,127.16 from CNY 21,152,087.39, a reduction of 40.56%[16] - The company recognized equity incentive expenses of CNY 41,848,400.00 in Q1 2023, which, when excluded, resulted in a net profit of CNY 111,898,500.00, a year-on-year increase of 63.76%[5] Income and Revenue - The company received government subsidies amounting to CNY 23,038,409.48, contributing to a 44% increase in other income compared to the previous year[7] - The company reported sales revenue from goods and services of CNY 2,132,989,639.88, an increase of 8.68% compared to CNY 1,961,929,624.33 in the previous period[19] Inventory and Receivables - Accounts receivable rose to CNY 2,203,335,198.97 from CNY 1,975,198,452.07, marking an increase of 11.53%[13] - Inventory levels increased to CNY 1,370,524,466.26 from CNY 1,220,415,814.43, which is a rise of 12.31%[13] Borrowings - Short-term borrowings increased to CNY 2,130,000,000.00 from CNY 1,882,000,000.00, reflecting a growth of 13.14%[14] Earnings Per Share - The basic and diluted earnings per share were both CNY 0.049, down from CNY 0.051 in the previous period, reflecting a decrease of approximately 3.92%[17]

Financial Performance - The company's operating revenue for 2022 was approximately ¥8.81 billion, representing an increase of 8.15% compared to ¥8.15 billion in 2021[19]. - Net profit attributable to shareholders reached approximately ¥350.14 million, a significant increase of 253.58% from ¥99.03 million in the previous year[19]. - The net profit after deducting non-recurring gains and losses was approximately ¥113.00 million, up 122.89% from ¥50.70 million in 2021[19]. - The cash flow from operating activities was approximately ¥1.11 billion, reflecting a growth of 48.50% compared to ¥746.51 million in 2021[19]. - Basic and diluted earnings per share were both ¥0.25, a substantial increase of 257.14% from ¥0.07 in the previous year[19]. - The total assets at the end of 2022 amounted to approximately ¥13.81 billion, an increase of 4.79% from ¥13.18 billion at the end of 2021[19]. - The net assets attributable to shareholders were approximately ¥4.56 billion, up 10.03% from ¥4.14 billion at the end of 2021[19]. - The weighted average return on equity for 2022 was 7.98%, an increase of 5.52 percentage points from 2.46% in 2021[19]. - The company reported non-operating income of CNY 237.1 million for 2022, a substantial increase from CNY 48.3 million in 2021[27]. - The company achieved operating revenue of 880,894.26 million yuan, an increase of 8.15% compared to the previous year[71]. - The net profit attributable to shareholders reached 35,014.37 million yuan, a significant increase of 253.58% year-on-year[71]. - R&D expenses amounted to 16,039 million yuan, representing a 92% increase from the previous year due to higher R&D spending[71]. - Financial expenses decreased to 791 million yuan, down 93% year-on-year, primarily due to exchange rate gains and reduced borrowing costs[71]. - The net cash flow from operating activities was 110,857 million yuan, an increase of 49% year-on-year, driven by higher sales revenue[72]. Market Position and Strategy - The company has indicated a positive outlook for future growth, driven by ongoing investments in new product development and market expansion strategies[5]. - The pharmaceutical manufacturing industry in China is expected to continue growing due to increased healthcare spending and an aging population[30]. - The company is positioned as a major player in the pharmaceutical sector, with a comprehensive product range including over 400 types of chemical raw materials and formulations[34]. - The company has established itself as a significant exporter, with products sold in over 100 countries and regions[34]. - The integration of raw materials and formulations is becoming a key trend in the pharmaceutical industry, driven by policy and cost control needs[32]. - The company aims to enhance its market position by leveraging advanced management practices and financial support from its controlling shareholder[33]. - The company is actively collaborating with the Chinese Academy of Medical Sciences on new applications for its products, such as glucose and lipid-lowering research[36]. - The company is expanding its online sales capabilities, leveraging competitive product resources to integrate online and offline sales channels[50]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[138]. - The company plans to invest in new product lines to drive future growth and improve overall performance[138]. Product Development and Innovation - The company has launched new products such as Carboprost Tromethamine, which is a first-line treatment for postpartum hemorrhage, further enhancing its gynecological product pipeline[37]. - The company has developed a series of anesthetic and psychotropic drugs, including the first domestic approval of hydromorphone injection, which is widely used for moderate to severe pain management[38]. - The company has implemented an intelligent manufacturing system for raw materials, enhancing production efficiency and product quality through automated and visual management[41]. - The company has a diverse product range in the health sector, including a variety of Vitamin C products, which have been developed into a comprehensive health product system[40]. - The company is focused on accelerating innovation and R&D efforts, with a goal of increasing the number of new product approvals and expanding into biopharmaceuticals[111]. - The company obtained multiple new drug registrations, including for drugs targeting cardiovascular and pain treatment, which are expected to enhance its product portfolio[84]. - Seven self-developed new products received approval, enhancing market share and laying a solid foundation for future growth[67]. - The company completed the verification and pilot scale-up of eight new product processes, with seven products passing consistency evaluation[67]. Sales and Marketing - The company has a comprehensive sales network and marketing team, with a focus on direct sales to end-users in the domestic market, ensuring effective market penetration[44]. - The sales model includes direct sales and distribution, with a focus on establishing direct relationships with end customers to reduce procurement costs[46]. - The pharmaceutical sales segment has optimized its marketing structure, implementing a refined management approach to quickly respond to market changes[47]. - The clinical division is organized into ten major regions, allowing for targeted marketing and sales strategies across different areas[47]. - The company maintains a focus on product line, terminal market, and profitability, adapting its sales strategies based on market supply and demand changes[45]. Corporate Governance and Compliance - The company has a modern corporate governance model that emphasizes market orientation and customer focus, enhancing its competitive capabilities[57]. - The governance structure of the company is robust, with a clear division of responsibilities among the board of directors, supervisory board, and management, ensuring compliance with legal and regulatory requirements[122]. - The company has implemented effective compensation policies to enhance operational goals and performance[127]. - The company has maintained a transparent and fair approach to information disclosure, safeguarding investors' rights[129]. - The company strictly adhered to information disclosure regulations, ensuring timely and accurate reporting of periodic and temporary announcements[130]. - The board of directors ensured compliance with corporate governance standards, with no significant discrepancies noted[130]. - The management team is committed to risk management and internal controls, regularly reporting to the board and implementing measures to ensure smooth execution of business plans[126]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[184]. - The company adheres to multiple environmental protection policies and industry standards, including the "14th Five-Year Plan" for energy conservation and emission reduction[185]. - The company has implemented various environmental protection measures in compliance with national laws and regulations[186]. - The company is actively involved in environmental impact assessments for its construction projects[187]. - The company reported a total wastewater discharge of 7,375.58 tons, with COD levels at 138.2384 mg/L, exceeding the standard of 300 mg/L[193]. - The total emissions of nitrogen oxides reached 36.14 tons, with a concentration of 190 mg/m³, which is above the permissible limit of 100 mg/m³[193]. - The company is focusing on improving its environmental performance by reducing emissions of sulfur dioxide to 11.56 tons, with a concentration of 100 mg/m³[193]. - The company plans to enhance its wastewater treatment processes to further reduce COD and ammonia levels in the future[193]. - The company is committed to expanding its market presence while ensuring sustainable practices in its operations[193]. Future Outlook - Future guidance indicates a positive outlook for revenue growth, driven by strategic initiatives and market expansion efforts[138]. - The company plans to develop new products and enhance existing product lines, with a focus on increasing market penetration and sales volume[106]. - The company aims to enhance operational efficiency through the establishment of new subsidiaries and strategic investments[101]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[140]. - The company is committed to maintaining high standards of corporate governance and transparency in its operations[140].

证券代码：000597 证券简称：东北制药 东北制药集团股份有限公司 投资者关系活动记录表 编号：2016-01 | --- | --- | --- | |----------------|------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ | 其他（深交所联合辽宁证监局在公司举办"践行中国梦·走 | | | 近上市公司" 投资者开放日） | | | 参与单位名称及 | 1 | 、国元证券、中国中投证券、申万宏源、中银国际证 | | 人员姓名 | 等报名的近 40 2 播、第 ...

证券代码：000597 证券简称：东北制药 东北制药集团股份有限公司 投资者关系活动记录表 编号：2017-01 | --- | --- | --- | |----------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | √现场参观 | | | 参与单位名称及 | | 莫尼塔医药张静含、华安基金陈江铃、中金公司邹朋、 oxbow 陶冶、 国联证券樊景扬、华富基金傅晟、中信产业基金李昱、五矿资本范 | | 人员姓名 | 方正证券田俊峰、泰达宏利周笑雯 | 宇、招商证券李勇剑、银河证券李平祝、王晓琦、安信证券周小刚、 | | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,149,397,962.51, representing a 2.57% increase year-over-year[7] - Net profit attributable to shareholders for Q3 2022 was ¥15,547,485.25, a significant increase of 144.57% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥32,044,788.42, up 185.66% year-over-year[7] - The company reported a significant increase in net profit for the first three quarters of 2022, reaching ¥128,138,875.00, which is a 402.55% increase year-over-year[7] - The net profit for the current period is 136,625,529.24, compared to 28,872,569.34 in the previous period, representing a significant increase[29] - The total profit for the current period is 208,566,887.34, up from 55,443,187.51 in the previous period, indicating strong operational performance[29] - The operating profit stands at 227,668,265.75, compared to 78,852,005.54 in the previous period, reflecting improved efficiency[29] - The total comprehensive income for the current period is 140,547,739.77, compared to 28,762,327.09 in the previous period, showing robust growth[32] Earnings and Shareholder Information - The company's basic earnings per share for Q3 2022 was ¥0.0104, an increase of 140.31% compared to the same period last year[7] - Basic earnings per share for the current period is 0.0939, compared to 0.0189 in the previous period, indicating enhanced profitability[32] - The total number of common shareholders at the end of the reporting period was 41,325[16] - The largest shareholder, Jiangxi Fangda Steel, holds 31.12% of shares, totaling 443,231,442 shares[16] - The second largest shareholder, Liaoning Fangda Group, holds 23.10% of shares, totaling 329,068,713 shares[16] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥15,236,406,756.49, reflecting a growth of 15.61% from the end of the previous year[7] - The company's total assets reached ¥15,236,406,756.49, up from ¥13,179,520,955.66, indicating a growth of 15.6%[26] - Total liabilities increased to ¥10,783,462,553.80 from ¥8,889,244,855.46, representing a rise of 21.3%[26] - The total current assets as of September 30, 2022, were approximately CNY 9.04 billion, an increase from CNY 6.80 billion at the beginning of the year[20] - The total non-current liabilities decreased to ¥456,766,569.03 from ¥690,643,300.37, a reduction of 33.8%[26] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥672,684,675.14, which is a 52.81% increase compared to the same period last year[7] - The cash flow from operating activities generated a net amount of 672,684,675.14, an increase from 440,218,469.84 in the previous period[33] - The net cash flow from investing activities is -174,993,183.29, an improvement from -580,488,137.61 in the previous period, indicating better investment management[35] - The net cash flow from financing activities is 677,219,616.16, compared to 454,196,622.11 in the previous period, reflecting effective capital raising efforts[35] Research and Development - Research and development expenses for the period were ¥56,580,000, marking a 66% increase year-over-year due to higher R&D investments[12] - Research and development expenses increased significantly to ¥56,583,004.82, compared to ¥34,009,934.42 in the previous period, marking a growth of 66.6%[27] Strategic Initiatives - The company implemented a restricted stock incentive plan in 2022, incurring equity incentive expenses of ¥39,308,000[7] - The company plans to establish a wholly-owned subsidiary with an investment of CNY 500 million to enhance international collaboration and innovation[19] - The company approved a stock incentive plan with an initial grant of 76.51 million shares at a price of CNY 2.716 per share[19] - The company is in the process of relocating its old factory and has signed a supplementary agreement with local government[19] - The company plans to continue expanding its market presence and investing in new product development[28] Inventory and Receivables - Accounts receivable increased to CNY 2.16 billion from CNY 1.85 billion year-to-date[20] - Inventory as of September 30, 2022, was CNY 1.30 billion, compared to CNY 1.25 billion at the beginning of the year[20]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 4,420,024,191.33, representing a 10.23% increase compared to CNY 4,009,707,128.71 in the same period last year[27]. - Net profit attributable to shareholders was CNY 112,591,389.75, an increase of 86.46% from CNY 60,384,107.93 year-on-year[27]. - The net cash flow from operating activities reached CNY 446,623,748.00, up 154.53% from CNY 175,472,940.77 in the previous year[27]. - Basic earnings per share increased to CNY 0.0835, an 85.56% rise compared to CNY 0.045 in the same period last year[27]. - Total assets at the end of the reporting period were CNY 14,807,748,755.58, a 12.35% increase from CNY 13,179,520,955.66 at the end of the previous year[27]. - The company's net assets attributable to shareholders were CNY 4,240,055,352.60, reflecting a 2.32% increase from CNY 4,143,733,863.20 at the end of the previous year[27]. - Non-recurring profit and loss for the period included CNY 76,071,868.43, which is a 63.07% increase from CNY 46,650,629.99 in the previous year[27]. - The weighted average return on net assets was 2.68%, up from 1.51% in the same period last year[27]. Market Position and Strategy - Northeast Pharmaceutical Group is a comprehensive pharmaceutical health industry group with a focus on "raw materials + formulations" integration, aiming to enhance cost control and core competitiveness[36]. - The company has a significant market presence, being one of China's largest single formulation production bases and exporting products to over 100 countries and regions[40]. - The company has developed over 400 types of chemical raw materials, intermediates, and formulation products, with leading products such as the world's largest producer of fosfomycin sodium, capturing over 80% of the domestic market share[41]. - The pharmaceutical manufacturing industry in China is expected to continue growing due to increasing healthcare awareness, aging population, and rising per capita consumption capacity[36]. - The company is positioned to benefit from the ongoing national centralized procurement policy, which is expected to lead to a healthier development of the pharmaceutical industry[36]. - The company is focusing on expanding its product offerings in the fields of anti-infection, reproductive system, and digestive system medications, with significant market shares in these areas[41]. Research and Development - The company has been actively involved in the research and development of new products, including the recently approved card prostaglandin aminopropanol, enhancing its product pipeline in the gynecology field[42]. - The company has established a national-level enterprise technology center and an innovative drug incubation base, enhancing its research capabilities[40]. - The company is advancing its R&D efforts through independent development, joint ventures, and project introductions to enhance the proportion of new product revenue[64]. - The company is planning to enhance its internal R&D capabilities and introduce new products, focusing on innovative and biological drugs, as well as strategic generic drugs[109]. Operational Efficiency - The company has implemented a comprehensive and precise production model, enhancing operational efficiency and product quality through an intelligent manufacturing system[51]. - The company has established a feedback platform to optimize service and improve efficiency in sales operations[61]. - The company has implemented a comprehensive cost control system across all stages, including R&D, procurement, production, and sales, to mitigate rising costs[110]. - The company has established a comprehensive equipment management system to enhance operational efficiency and reduce costs[79]. Environmental Responsibility - The company has implemented a safety and environmental responsibility system, enhancing its environmental protection measures and monitoring capabilities[78]. - The company has maintained compliance with pollution discharge standards, with no exceedances reported in wastewater and air emissions[129]. - The company has invested CNY 340 million since Q4 2020 to enhance environmental performance, focusing on air, water, and comprehensive utilization projects[168]. - The wastewater treatment facility at the Xihe plant covers an area of 120,000 square meters and utilizes advanced MBR membrane bioreactor technology to meet production wastewater treatment needs[168]. Corporate Governance and Independence - Northeast Pharmaceutical Group maintained the independence of its operations, ensuring that its business activities are not influenced by the parent company or other controlled enterprises[191]. - The company guarantees the independence of its financial accounting department and financial management system, maintaining separate bank accounts from related enterprises[194]. - The company has committed to not using the funds or assets of the listed company unlawfully, ensuring the protection of its legal property rights[198]. - The company has established a framework to ensure that it can operate independently in the market, with the necessary assets, personnel, and capabilities[191].